Terms: = Head and neck cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Prognosis
17 results:
1. Pseudogene Transcripts in head and neck cancer: Literature Review and
Carron J; Della Coletta R; Lourenço GJ
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440428
[TBL] [Abstract] [Full Text] [Related]
2. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Significance of CUB and Sushi Multiple Domains 1 Inactivation in head and neck Squamous Cell Carcinoma.
Jung AR; Eun YG; Lee YC; Noh JK; Kwon KH
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30545040
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract] [Full Text] [Related]
5. Somatic Host Cell Alterations in HPV Carcinogenesis.
Litwin TR; Clarke MA; Dean M; Wentzensen N
Viruses; 2017 Aug; 9(8):. PubMed ID: 28771191
[TBL] [Abstract] [Full Text] [Related]
6. hla-a*02-B*46 haplotype: an adverse prognostic factor in Han patients with nasopharyngeal carcinoma.
Wang RZ; Zhang DG; Wu R; Hu YH; Peng YC; Chang C; Dong T; Wang XY
J Huazhong Univ Sci Technolog Med Sci; 2016 Oct; 36(5):700-704. PubMed ID: 27752910
[TBL] [Abstract] [Full Text] [Related]
7. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y; Fukuma D; Yuno A; Hirayama M; Nakayama H; Tanaka T; Nagata M; Takamune Y; Kawahara K; Nakagawa Y; Yoshida R; Hirosue A; Ogi H; Hiraki A; Jono H; Hamada A; Yoshida K; Nishimura Y; Nakamura Y; Shinohara M
Clin Cancer Res; 2015 Jan; 21(2):312-21. PubMed ID: 25391695
[TBL] [Abstract] [Full Text] [Related]
8. The MAPK pathway is a predominant regulator of hla-a expression in esophageal and gastric cancer.
Mimura K; Shiraishi K; Mueller A; Izawa S; Kua LF; So J; Yong WP; Fujii H; Seliger B; Kiessling R; Kono K
J Immunol; 2013 Dec; 191(12):6261-72. PubMed ID: 24244023
[TBL] [Abstract] [Full Text] [Related]
9. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.
Kono K; Iinuma H; Akutsu Y; Tanaka H; Hayashi N; Uchikado Y; Noguchi T; Fujii H; Okinaka K; Fukushima R; Matsubara H; Ohira M; Baba H; Natsugoe S; Kitano S; Takeda K; Yoshida K; Tsunoda T; Nakamura Y
J Transl Med; 2012 Jul; 10():141. PubMed ID: 22776426
[TBL] [Abstract] [Full Text] [Related]
10. Expression of heat shock protein 70 in nasopharyngeal carcinomas: different expression patterns correlate with distinct clinical prognosis.
Cai MB; Wang XP; Zhang JX; Han HQ; Liu CC; Bei JX; Peng RJ; Liang Y; Feng QS; Wang HY; Chen LZ; Fu S; Kang T; Shao JY; Zeng YX
J Transl Med; 2012 May; 10():96. PubMed ID: 22591702
[TBL] [Abstract] [Full Text] [Related]
11. Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma.
Zhang X; Lin A; Zhang JG; Bao WG; Xu DP; Ruan YY; Yan WH
Int J Cancer; 2013 Jan; 132(1):82-9. PubMed ID: 22544725
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
[TBL] [Abstract] [Full Text] [Related]
13. Novel immunogenic hla-a*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.
Andrade Filho PA; López-Albaitero A; Gooding W; Ferris RL
J Immunother; 2010 Jan; 33(1):83-91. PubMed ID: 19952953
[TBL] [Abstract] [Full Text] [Related]
14. Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study.
Tisch M; Kyrberg H; Weidauer H; Mytilineos J; Conradt C; Opelz G; Maier H
Laryngoscope; 2002 Apr; 112(4):651-7. PubMed ID: 12150518
[TBL] [Abstract] [Full Text] [Related]
15. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
Concha A; Esteban F; Cabrera T; Ruiz-Cabello F; Garrido F
Semin Cancer Biol; 1991 Feb; 2(1):47-54. PubMed ID: 1912518
[TBL] [Abstract] [Full Text] [Related]
16. Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx.
Esteban F; Concha A; Delgado M; Pérez-Ayala M; Ruiz-Cabello F; Garrido F
Br J Cancer; 1990 Dec; 62(6):1047-51. PubMed ID: 2257212
[TBL] [Abstract] [Full Text] [Related]
17. [Immunologic modulation of tumor aggressiveness in cancer of the larynx. II. Clinicopathologic correlations with the loss of expression of the HLA ABC antigens].
Esteban F; Concha A; Delgado M; Ruiz-Cabello F; Garrido F
Acta Otorrinolaringol Esp; 1990; 41(6):359-68. PubMed ID: 2092725
[TBL] [Abstract] [Full Text] [Related]
